By Sarah Roden Valeant Pharmaceuticals (NYSE:VRX) beat out Endo International in a battle to take over Salix Pharmaceuticals (NASDAQ:SLXP) in a deal valued …
A handful of bio-pharmaceutical stocks are announcing their financial results for the final quarter of 2014 this week. What should investors watch for?
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all …
(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix” or the “Company”) today announced the promotion of William P.
(BUSINESS WIRE)–Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 …
In a research report issued today, Cantor analyst Irina Rivkind reiterated a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP), but reduced her price target to $127 …
In a research report issued today, Roth Capital analyst Scott Henry downgrades shares of Salix Pharmaceuticals (NASDAQ:SLXP) from Buy to Hold and reduced his price …
In a research report released today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a price target …
In a research report issued today, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $184 price target, following today’s …
In a research report published today, Cantor Fitzgerald analyst Irina Rivkind reiterated her Buy rating on Salix Pharma (NASDAQ:SLXP) and increased her price …